Biofrontera Inc. to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025
Rhea-AI Summary
Biofrontera (NASDAQ:BFRI), a biopharmaceutical company focused on dermatological products commercialization, has announced its participation in the upcoming Lytham Partners Fall 2025 Investor Conference on September 30, 2025.
The company will deliver a webcast presentation at 1:15 p.m. ET and conduct one-on-one meetings with investors throughout the virtual event. Investors can access the webcast through the conference website or directly via the provided link, with replay available after the event.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, BFRI declined 0.02%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Woburn, MA, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc., (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that it will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2025 Investor Conference, taking place virtually on Tuesday, September 30, 2025.
Company Webcast
The webcast presentation will take place at 1:15 p.m. ET on Tuesday, September 30, 2025. The webcast can be accessed by visiting the conference home page at https://lythampartners.com/fall2025/ or directly at https://app.webinar.net/wWqPp4Yr0kD. The webcast will also be available for replay following the event.
1x1 Meetings
Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1x1@lythampartners.com or register for the event at https://lythampartners.com/fall2025invreg/.
About Biofrontera Inc.
Biofrontera Inc. is a U.S.-based biopharmaceutical company specializing in the development and treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz ® with the RhodoLED ® lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. The Company performs clinical trials to extend the use of the products to treat non-melanoma skin cancers and moderate to severe acne. For more information, visit www.biofrontera-us.com and follow Biofrontera on LinkedIn and X.
Investor Relations Contact
Ben Shamsian
Lytham Partners
646-829-9701
shamsian@lythampartners.com
FAQ
When is Biofrontera (BFRI) presenting at the Lytham Partners Fall 2025 Conference?
How can investors access Biofrontera's (BFRI) conference presentation?
Will Biofrontera (BFRI) management be available for individual meetings during the conference?
What type of company is Biofrontera (BFRI)?
